Therapeutic benefits of combination chemotherapy with vincristine, BCNU, and procarbazine on recurrent cystic craniopharyngioma

Bremer, Alfonso M.; Nguyen, Tai Q.; Balsys, Raymond

doi:10.1007/bf00165157

Cited by 23 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Complications of intralesional chemotherapeutic treatment have been reported to be associated with the toxic effects of bleomycin on the hypothalamus, 48 as in a case in which, after intracystic injection of bleomycin, a patient developed hypersomnia, personality changes, memory impairment, and thermal dysfunction. Bremer, et al, 14 have reported finding neurological improvement and decreased cyst size following systemic combination treatment with vincristine, carmustine (BCNU), and procarbazine.…”

Section: Neurosurg Focus / Volume 12 / May 2002mentioning

confidence: 99%

Tumors of the skull base in children: review of tumor types and management strategies

Tsai¹,

Santoreneos²,

Rutka³

2002

FOC

View full text Add to dashboard Cite

Although many treatment strategies for skull base tumors in adults have been reported, relatively little has been reported regarding such therapies in the pediatric population. Skull base tumors in children present a therapeutic challenge because of their unique pathological composition, the constraints of the maturing skull and brain, and the small size of the patients. In this review, the authors examine the pediatric skull base lesions that occur in the anterior, middle, and posterior cranial base, focusing on unique pediatric tumors such as encepahalocele, fibrous dysplasia, esthesioneuroblastoma, craniopharyngioma, juvenile nasopharyngeal angiofibroma, cholesteatoma, chordoma, chondrosarcoma, and Ewing sarcoma. They review management strategies that include radio- and chemotherapy, as well as surgical approaches with emphasis on the modifications and complications associated with the procedures as they apply in children. Evidence for the advantages and limitations of radiotherapy, chemotherapy, and surgery as it pertains to the pediatric population will be examined. With a working knowledge of skull base anatomy and special considerations of the developing craniofacial skeleton, neurosurgeons can treat skull base lesions in children with acceptable morbidity and mortality rates. Outcomes in this population may be better than those in adults, in part because of the benign histopathology that frequently affects the pediatric skull base, as well as the plasticity of the maturing nervous system.

show abstract

Section: Neurosurg Focus / Volume 12 / May 2002mentioning

confidence: 99%

Tumors of the skull base in children: review of tumor types and management strategies

Tsai¹,

Santoreneos²,

Rutka³

2002

FOC

View full text Add to dashboard Cite

show abstract

“…Bremer et al treated a case of cystic craniopharyngioma with systemic chemotherapy using the combination of vincristine, carmustine and procarbazine, resulting in tumor shrinkage and clinical improvement [22]. Lippens et al reported four cases of adamantinomatous craniopharyngioma with multiple recurrences after several surgical procedures and RT.…”

Section: Discussionmentioning

confidence: 98%

MGMT immunoexpression in adamantinomatous craniopharyngiomas

et al. 2011

View full text Add to dashboard Cite

At present, no effective medical treatment exists for recurrent and aggressive craniopharyngiomas that are resistant to conventional therapies, including surgery and adjuvant radiotherapy. Temozolomide is an alkylating chemotherapeutic agent used routinely in the management of high grade gliomas. The response to temozolomide is suggested to be dependent on the tumoral expression of O-6 methylguanine DNA methyltransferase (MGMT). Evidence supports that low MGMT immunoexpression correlates with positive response to temozolomide. Therefore, we aimed to assess MGMT immunoexpression in adamantinomatous craniopharyngiomas, in an effort to predict the likelihood of response to temozolomide. The MGMT immunostaining was performed on 23 adamantinomatous craniofaryngiomas operated at the Sisli Etfal Training and Research Hospital and identified by histological analysis. Paraffin embedded tissue sections were immunostained for MGMT and were evaluated semi-quantitatively. Of the 23 cases evaluated, 22 (96%) demonstrated negative (<10%) and 1 (4%) demonstrated low (10%) MGMT immunoexpression. Data from this study suggest a high proportion of adamantinomatous craniopharyngiomas exhibit negative/low MGMT immunoreactivity and could be treated with temozolomide, if conventional therapy fails.

show abstract

“…Significant and persistent reduction in tumour size has been recorded in response to systemic therapy with BCNU, vineristine and procarbazine in combination (Bremer et al, 1984) and to nitrogen mustard, vineristine, procarbazine and prednisolone in combination (Fischer et al, 1990). Responses to intracavitary methotrexate (Constine et al, 1989) and to bleomycin (Broggi et al, 1989) have been observed and in one series seven children with cystic craniopharyngiomas showed durable responses to intracyst bleomycin given as the primary treatment (Takahashi et al, 1985).…”

Section: Radiation Therapymentioning

confidence: 96%

Management of Brain Tumours in Childhood

Punt¹

1995

Malignant Brain Tumours

View full text Add to dashboard Cite

Therapeutic benefits of combination chemotherapy with vincristine, BCNU, and procarbazine on recurrent cystic craniopharyngioma

Cited by 23 publications

References 26 publications

Tumors of the skull base in children: review of tumor types and management strategies

Tumors of the skull base in children: review of tumor types and management strategies

MGMT immunoexpression in adamantinomatous craniopharyngiomas

Management of Brain Tumours in Childhood

Contact Info

Product

Resources

About